(MENAFN- GetNews)


"Chronic Obstructive Pulmonary Disease (COPD) Market Projected to Grow by 2034"Chronic Obstructive Pulmonary Disease companies are Regeneron, United Therapeutics, Verona Pharma, Inmunotek, Tetherex, Novartis, Organicell Regenerative Medicine, Vertex, Pulmotect, Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others.

The growth of the chronic obstructive pulmonary disease (COPD) market is driven by factors such as rising disease prevalence, increased investments in research and development, and the introduction of innovative therapies over the forecast period from 2020 to 2034.

The market report provides in-depth insights into COPD, including market size, share, epidemiology, emerging therapies, key drivers and barriers, ongoing clinical trials, strategic collaborations, and the adoption of therapies by companies actively contributing to market growth.

Some of the key highlights from the Chronic Obstructive Pulmonary Disease Market Insights Report:

Several leading pharmaceutical companies, including AstraZeneca/Circassia, GlaxoSmithKline/Theravance/Innoviva, Chiesi Farmaceutici, Sunovion, Boehringer Ingelheim, Sanofi/Regeneron, United Therapeutics, Verona Pharma, Inmunotek, Tetherex, Novartis, Organicell Regenerative Medicine, Vertex, Pulmotect, Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others, are actively developing innovative therapies to improve the treatment landscape for chronic obstructive pulmonary disease (COPD).

The COPD market was valued at approximately USD 16.1 billion in 2023 and is expected to grow steadily during the forecast period (2024–2034), driven by rising diagnosis rates and the introduction of novel therapies. According to DelveInsight, around 41% of diagnosed COPD cases in the 7MM were in the United States, while the EU4 and the UK together accounted for roughly 18.6 million cases in 2023.

The 7MM COPD market is primarily segmented into three treatment categories: Monotherapies (e.g., LABA, LAMA), Double Combination Therapies (e.g., LABA + ICS, LABA + LAMA), and Triple Combination Therapies (LABA + LAMA + ICS). Among these, Double Combination Therapies generated the highest revenue in 2023, totaling approximately USD 8.8 billion.

Market growth is further supported by the emergence of more effective therapies, including Itepekimab (SAR440340/REGN3500), FASENRA (benralizumab), and NUCALA (mepolizumab). Key milestones include:

• October 2024 – FDA approval of the first monoclonal antibody for COPD

• September 2024 – Sanofi/Regeneron's Dupixent received the first biologic approval for COPD

• May 2024 – AstraZeneca presented research on major respiratory and immune-mediated diseases at ATS 2024, highlighting studies on benralizumab for COPD treatment

According to DelveInsight, the COPD market is expected to witness significant growth at a notable CAGR over the forecast period.

Strategise your business goals by understanding market dynamics @ Chronic Obstructive Pulmonary Disease Market Landscape

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and limited airflow. It arises from structural changes in the airways and/or alveoli, often caused by long-term exposure to harmful particles or gases. COPD develops through complex pathological processes, resulting in distinct subtypes with unique features and disease progression patterns. These differences lead to varying rates of exacerbations, degrees of airflow limitation, and levels of lung function impairment, making effective management of the disease a significant challenge.

Do you know the treatment paradigms for different countries? Download our Chronic Obstructive Pulmonary Disease Market Sample Report

Chronic Obstructive Pulmonary Disease Epidemiology Insights

• According to DelveInsight, there were approximately 44.2 million diagnosed cases of COPD across the seven major markets (7MM) in 2023.

• The United States recorded the highest prevalence, with an estimated 18.3 million diagnosed cases that year. This number is expected to increase over the forecast period, driven by factors such as rising smoking rates, improved diagnostic capabilities, and heightened patient awareness.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation

DelveInsight's Chronic Obstructive Pulmonary Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Obstructive Pulmonary Disease historical patient pools and forecasted Chronic Obstructive Pulmonary Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Obstructive Pulmonary Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Chronic Obstructive Pulmonary Disease Prevalence

• Age-Specific Chronic Obstructive Pulmonary Disease Prevalence

• Gender-Specific Chronic Obstructive Pulmonary Disease Prevalence

• Diagnosed and Treatable Cases of Chronic Obstructive Pulmonary Disease

Visit for more @ Chronic Obstructive Pulmonary Disease Epidemiological Insights

Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable lung disorder affecting both men and women worldwide. It is marked by airflow limitation caused by airway narrowing, inflammation, mucus accumulation, and lung tissue damage. COPD shares symptoms with asthma, including coughing, wheezing, and shortness of breath, and some individuals may experience both conditions.

Mild cases may require little more than smoking cessation, while more advanced stages are managed with therapies aimed at controlling symptoms, slowing disease progression, and reducing complications. Treatment focuses on improving breathing and overall quality of life through a combination of medications, lifestyle changes, and supportive approaches. Management is tailored to disease stage, emphasizing symptom relief and infection prevention.

Prevention-especially quitting smoking-is critical to slowing COPD progression. Regular exercise can strengthen respiratory muscles and enhance overall well-being. Pharmacologic management includes maintenance therapies (such as inhaled corticosteroids, long-acting beta-agonists, and combination treatments) and reliever medications (including short-acting beta-agonists, oral corticosteroids, and nebulized therapies).

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca

• DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals

• FASENRA (benralizumab): AstraZeneca

Chronic Obstructive Pulmonary Disease Key Companies: AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others

For more information, visit Chronic Obstructive Pulmonary Disease Market Analysis , Patient Pool, and Emerging Therapies

Scope of the Chronic Obstructive Pulmonary Disease Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Chronic Obstructive Pulmonary Disease, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Chronic Obstructive Pulmonary Disease epidemiology in the 7MM

• Chronic Obstructive Pulmonary Disease marketed and emerging therapies

• Chronic Obstructive Pulmonary Disease companies

• Chronic Obstructive Pulmonary Disease market drivers and barriers

Table of Contents:

1 Chronic Obstructive Pulmonary Disease Market Key Comprehensive Insights

2 Chronic Obstructive Pulmonary Disease Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Obstructive Pulmonary Disease

4 Chronic Obstructive Pulmonary Disease Market Analysis Overview at a Glance

5 Executive Summary of Chronic Obstructive Pulmonary Disease

6 Chronic Obstructive Pulmonary Disease Epidemiology and Market Methodology

7 Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

8 Chronic Obstructive Pulmonary Disease Patient Journey

9 Chronic Obstructive Pulmonary Disease Treatment Algorithm, Chronic Obstructive Pulmonary Disease Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Obstructive Pulmonary Disease Clinical Trials

11 Chronic Obstructive Pulmonary Disease Marketed Therapies

12 Chronic Obstructive Pulmonary Disease Emerging Therapies

13 Chronic Obstructive Pulmonary Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Obstructive Pulmonary Disease

16 Chronic Obstructive Pulmonary Disease Market Key Opinion Leaders Reviews

18 Chronic Obstructive Pulmonary Disease Market Drivers

19 Chronic Obstructive Pulmonary Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Obstructive Pulmonary Disease Epidemiology 2034

DelveInsight's "Chronic Obstructive Pulmonary Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Obstructive Pulmonary Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Obstructive Pulmonary Disease Pipeline 2024

"Chronic Obstructive Pulmonary Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Obstructive Pulmonary Disease market. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided, which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines.

MENAFN09102025003238003268ID1110176200